Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
Exelixis reported Q1 2026 total revenue of $610.8 million, up 10% year-over-year, driven by Cabomantinib franchise net product revenues of $555.0 million. GAAP diluted EPS was $0.79 and Non-GAAP diluted EPS was $0.87, representing significant increases from the prior year.
Key figures
- Eps
- 0.79
- Revenue
- 610800000
- Guidance
- 2026 Total revenues $2.525B - $2.625B; Net product revenues $2.325B - $2.425B
- Revenue Yoy
- 10%
- Rd expenses
- 199900000
- Non gaap eps
- 0.87
- Net product revenues
- 555000000
- Collaboration revenues
- 55800000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.